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Traumatic optic neuropathy (TON) is an uncommon cause of visual loss following blunt or penetrating
head trauma, but the consequences can be devastating, especially in cases with bilateral optic nerve
involvement. Although the majority of patients are young adult males, about 20% of cases occur during
childhood. A diagnosis of TON is usually straightforward based on the clinical history and examination
ﬁndings indicative of an optic neuropathy. However, the assessment can be difﬁcult when the patient's
mental status is impaired owing to severe trauma. TON frequently results in profound loss of central
vision, and the ﬁnal visual outcome is largely dictated by the patient's baseline visual acuities. Other poor
prognostic factors include loss of consciousness, no improvement in vision after 48 hours, the absence of
visual evoked responses, and evidence of optic canal fractures on neuroimaging. The management of
TON remains controversial. Some clinicians favor observation alone, whereas others opt to intervene
with systemic steroids, surgical decompression of the optic canal, or both. The evidence base for these
various treatment options is weak, and the routine use of high-dose steroids or surgery in TON is not
without any attendant risks. There is a relatively high rate of spontaneous visual recovery among patients
managed conservatively, and the possible adverse effects of intervention therefore need to be even more
carefully considered in the balance.
Copyright © 2015, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Classiﬁcation
Traumatic optic neuropathy (TON) refers to any insult to the
optic nerve secondary to trauma. It can be classiﬁed depending on
the site of injury (optic nerve head, intraorbital, intracanalicular, or
intracranial) or according to the mode of injury (direct or indi-
rect).1,2 In direct TON, there is signiﬁcant anatomical disruption to
the optic nerve, for example, from a projectile penetrating the orbit
at high velocity (Fig. 1), or as a result of optic nerve avulsion (Fig. 2).
Indirect TON is caused by the transmission of forces to the optic
nerve from a distant site, without any overt damage to the sur-
rounding tissue structures. The deformative stress transmitted tocial disclosures or conﬂicts of
h, Institute of Genetic Medi-
le upon Tyne, NE1 3BZ, UK.
ciety of Taiwan. Published by Elsevthe skull from blunt trauma is concentrated in the region of the
optic canal. The intracanalicular segment of the optic nerve is
particularly susceptible to this form of injury, because the dural
sheath is tightly adherent to the periosteum at this speciﬁc loca-
tion.3,4 The intracranial portion of the optic nerve in close proximity
to the falciform dural fold is the next most common site at risk of
injury.5 In one report using computerized tomography (CT) imag-
ing, about half of all TON cases were found to have an associated
sphenoidal bone fracture, an indirect measure of the signiﬁcant
compressive forces involved at impact.6 However, both direct and
indirect mechanisms can contribute to optic nerve damage, and a
clear distinction is not always possible.2. Pathophysiology
The pathophysiology of indirect TON is likely to be multifacto-
rial, and the concept of primary and secondary injury has been
proposed.7,8 Following trauma, there is an immediate shearing of aier Taiwan LLC. All rights reserved.
Fig. 1. Direct traumatic optic neuropathy. (A) Entry site of a projectile in the medial canthal region of the right eye. (B) The patient's posterior pole was normal when he was
assessed shortly after the accident. His visual acuity at that time was no perception of light. (C) Conjunctival scar over the entry site. (D) Optic disc pallor, more marked temporally,
was apparent 6 weeks later. The patient's visual acuity had not improved and he was subsequently lost to follow-up. (Courtesy of Professor David Taylor, Institute of Child Health,
London, UK.)
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that results in neuronal loss. There is then a degree of optic nerve
swelling within the tight conﬁnes of the optic canal secondary to
direct mechanical trauma and vascular ischemia. The ensuing
compartment syndrome further impairs the already compromised
blood supply to surviving retinal ganglion cells, setting up a
downward spiral toward apoptotic cell death. This two-stagemodel
of TON forms the basis for optic nerve decompression bymedical or
surgical means, in order to break this vicious cycle and to preserve
the remaining retinal ganglion cells that survived the initial insult.
3. Epidemiology
TON is an uncommon cause of visual loss following blunt or
penetrating head trauma with a reported incidence of 0.7e2.5% in
published case series.9e12 A recent national epidemiological survey
of TON in the United Kingdom found a minimum prevalence in the
general population of one in 1,000,000.13 The vast majority of
affected patients are young adult males (79e85%) in their early 30s.
The most common causes of TON in this patient group are motor
vehicle and bicycle accidents (49%), falls (27%), and assaultsFig. 2. Traumatic optic nerve avulsion following a road trafﬁc accident. (Courtesy of Dr
Scott Schoenberger, Vanderbilt Eye Institute, Nashville, TN, USA.)(13%).13,14 In the pediatric population, the majority of TON cases are
secondary to falls (50%) and road trafﬁc accidents (40%).154. Clinical assessment
TON is a clinical diagnosis supported by a history of direct or
indirect trauma to the head or face. The injury can sometimes be
trivial, and a careful history of the incident must be elicited from
the patient and any other witnesses that might have been present
especially when dealing with children or unconscious patients. A
detailed record should also be kept as cases of TON are not infre-
quently the subject of future medicolegal proceedings. Although
usually straightforward, the clinical assessment can sometimes
prove difﬁcult in the setting of severe trauma when the patient's
level of consciousness is impaired. In this scenario, it is essential to
exclude possible reversible causes of visual loss that require im-
mediate attention, for example, a retrobulbar hemorrhage. The
patient's baseline visual acuity should be clearly documented in the
notes and even if only a bedside examination is possible, this can
still be achieved with a portable vision chart and the use of a
pinhole occluder. A thorough examination of the eye and the
adnexal structures is mandatory, with particular care taken to
exclude associated orbital or facial fractures requiring more
specialized maxillofacial input. Except when neurosurgical moni-
toring of the pupil is required, a detailed dilated examination of the
posterior pole must be carried out to document the state of the
optic disc, any associated retinal or vitreous hemorrhages, and the
possibility of an intraocular foreign body in cases of penetrating
trauma. A high degree of clinical vigilance must also be maintained
because TON can infrequently be associated with delayed visual
loss secondary to the development of an optic nerve sheath he-
matoma (Fig. 3). The following features are consistent with a
diagnosis of TON. (1) Unilateral or bilateral ocular involvement. (2)
A relative afferent pupillary defect except in bilateral symmetric
cases. A relative afferent pupillary defect is an important clinical
sign, and in patients with mild TON, it can be the only objective
evidence of optic nerve dysfunction prior to the development of
overt optic atrophy. (3) Variable loss of visual acuity ranging from
normal to no light perception. Between 40% and 60% of patients
present with severe visual loss of light perception or worse at
baseline.13e17 (4) Impairment of color vision. (5) Variable visual
ﬁeld defects.
Fig. 3. Right optic nerve sheath hematoma. (Courtesy of Dr Peter Savino, Wills Eye
Institute, Philadelphia, PA, USA.)
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and the timing of injury. With injuries to the optic nerve anterior to
the entry point of the central retinal vessels, there is optic disc
swelling with associated retinal hemorrhages. With more posterior
injuries, which are more common, the fundus can look entirely
normal. Optic disc pallor usually develops about 6 weeks following
the initial injury (Fig. 1).5. Neuroimaging
There is a wide variation in practice worldwide regarding the
use of neuroimaging in TON. Some clinicians request CT or mag-
netic resonance imaging or both for all cases, whereas others limit
these investigations to patients with progressive visual deteriora-
tion or when therapeutic interventions are being considered.6,18,19
Before a magnetic resonance imaging is carried out, it is essential
to exclude the possibility of an intraorbital or intraocular metallic
foreign body by conventional radiography. CT is the best imaging
modality for delineating optic canal fractures and their full extent
in preparation for possible surgical intervention (Fig. 4). However,
the clinical usefulness of universal neuroimaging in TON remains
debatable as there is no consistent correlation between the ﬁndingFig. 4. Optic canal fracture and optic nerve compression. (A) Axial computerized tomograp
lateral wall of the right orbit. The bone fragment is causing compression of the right optic ne
left side (clear arrow). (B) Coronal CT scan showing narrowing of the right optic foramen (
compression of the right optic nerve by the bone fragment. (Courtesy of Dr Manjunatha YCof an optic canal fracture, the severity of visual loss, and the
prognosis for visual recovery.20,21
6. Prognostic factors
A visual recovery rate of 40e60% has been reported for indirect
TON cases managed conservatively, with baseline visual acuity
being the most important predictor of ﬁnal outcome.14,22e26 There
is a signiﬁcant correlation between initial and ﬁnal visual acuities,
and patients reporting no light perception at presentation invari-
ably have limited or no visual improvement. Other poor prognostic
factors include loss of consciousness, lack of visual recovery after 48
hours, and absence of visual evoked responses.26,27 The presence of
an optic canal fracture was found to predict a poor visual outcome
in some, but not all, case series.16,22,26,28,29 Direct TON is a distinct
category that results in severe, irreversible visual loss with little
likelihood for recovery, and no intervention is of proven beneﬁt.
7. Management
The controversies surrounding the optimal management of TON
have been the subject of recent Cochrane systematic reviews.20,21
Despite these persisting uncertainties, the main treatment op-
tions in current use for TON are as follows: (1) systemic steroids of
varying doses, duration, and mode of administration; (2) surgical
decompression of the optic canal; (3) a combination of steroids and
surgery; and (4) observation alone (i.e., conservative management).
8. Steroids
The pharmacological rationale for using steroids in TON ﬁrst
arose from their perceived beneﬁts when applied to various animal
models of central nervous system injuries.30,31 The observed neu-
roprotective effect has been ascribed to the antioxidant properties of
steroids and to the inhibition of free radical-induced lipid peroxi-
dation.32,33 This hypothesis was further reinforced following the
clinical introduction of steroids to the treatment of traumatic spinal
cord injuries. The second National Acute Spinal Cord Injury Study
(NASCIS-II) was a multicenter, randomized, double-blind, placebo-
controlled trial set up to assess the beneﬁts of megadose steroids in
patients with acute spinal cord injury.34 The treatment regimen
consisted of an initial bolus dose of 30 mg/kg, followed by an infu-
sion at 5.4 mg/kg/h for a total duration of 23 hours. Patients whohy (CT) scan through the optic nerves showing a fracture in the posterior part of the
rve within the optic canal (white arrow). A normal wide optic canal can be seen on the
white arrow) compared with the left side (clear arrow). (C) Sagittal CT scan showing
, Sri Devaraj Urs Medical College, Tamaka, Kolar, India.)
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better improvement in neurological functions compared to those in
the placebo group or those who were treated after 8 hours.34 In the
thirdNASCIS (NASCIS-III), patients who received steroids 3e8 hours
after their injury experienced greatermotor and functional recovery
when this regimen was maintained for 48 hours instead of 24
hours.35 For those patients who were treated within 3 hours of
injury, the neurological outcomes in the 24- and48-hour armsof the
trial were similar. Unsurprisingly, the ﬁndings of the NASCIS trials
have heavily inﬂuenced clinical practice, leading to the increased
use of steroids in TON from the mid-1990s onward.
9. Steroid regimens
Steroids have been used both on its own and in combination
with surgical optic nerve decompression either pre-, intra-, or
postoperatively.20,21 Based on the initial daily dose of methyl-
prednisolone used, steroid regimens can be classiﬁed as: (1) low
dose (< 100 mg), (2) moderate dose (100e499 mg), (3) high dose
(500e1999 mg), (4) very high dose (2000e5399 mg), or (5)
megadose (> 5400 mg). The most commonly used steroid protocol
in TON is a course of intravenous methylprednisolone in the very
high-dose to megadose range.
10. Critical analysis
All the published case series in TON suffer from several meth-
odological ﬂaws.13,14,16,22,23,36 The majority are small, retrospective
studies that lack the sample size for rigorous statistical analysis,
and the absence of adequate randomization introduces the added
possibility of selection bias. It is also very difﬁcult to compare the
results, even qualitatively, because of the wide range of steroid
regimens used and the variable time allowed prior to the initiation
of treatment. A Cochrane systematic review identiﬁed only one
double-blind, randomized controlled trial comparing high-dose
intravenous steroids to placebo in patients with indirect TON
diagnosed within 7 days of their initial injuries.21 Although this
study was relatively small, with only 16 patients in the treated
group and 15 patients in the placebo group, therewas no signiﬁcant
difference in the ﬁnal visual outcome between these two groups,
precluding a major therapeutic effect from the use of steroids.37
11. International Optic Nerve Trauma Study
The International Optic Nerve Trauma Study (IONTS) is the
largest, prospective, multicenter study of TON published to date.14
It was intended to be a randomized controlled trial, but it had to
be converted to an observational study after 2 years owing to
recruitment failure. The analysis included a total of 133 people with
indirect TON treated within 7 days of injury and categorized into
three groups: untreated (n ¼ 9), steroids (n ¼ 85), or optic canal
decompression surgery (n ¼ 33). The majority of patients in the
steroid group had either a megadose (40%) or very high-dose
regimen (18%), and all the participants in the surgical group,
except for one, also received steroids. Follow-up datawere available
for 104 cases at 1 month and for 40 cases at 6 months. After
adjustment for baseline visual acuity, no signiﬁcant differences
were found between the three treatment groups. A three-line in-
crease in visual acuity or more occurred in 57% of the untreated
group, 52% of the steroid group, and 32% of the surgery group.14
Interestingly, there was no trend suggesting an increased proba-
bility of visual recovery with higher doses of steroids or with earlier
initiation of treatment. Although some case series have reported
higher improvement rates with steroids, most published ﬁgures
(44e62%) are comparable with IONTS.13,16,22,23,36 Crucially, none ofthese studies have demonstrated any convincing functional visual
beneﬁt following treatment with steroids.
12. NASCIS
The application of steroids toTON relies heavily on extrapolation
made from the NASCIS trials, and therefore a critical appraisal of
their results is appropriate.34,35 There is ongoing debate in the
literature regarding the signiﬁcance of the neurological beneﬁt
reported by NASCIS among patients treated within the 8-hour
window of sustaining a spinal cord injury.38e41 The mean differ-
ence between the steroid and the placebo groups indicated a sig-
niﬁcant neurological beneﬁt for motor scores, but not for sensory
scores. Critics of the NASCIS trials have argued that the ﬁnding of a
beneﬁcial effect for the early treatment group is relatively weak,
being based on a post hoc subgroup analysis.38e41 Concerns have
also been raised on possible randomization imbalance between the
treatment arms, which might have biased the results in favor of the
steroid group. For clinicians, perhaps the most compelling argu-
ment is that although statistically signiﬁcant, the relatively small
change in motor scores might not actually translate into any
functional beneﬁt. A Cochrane systematic review on the use of
steroids following acute spinal cord injury has not resolved the
controversy surrounding the NASCIS trials.42 The optic nerve is a
predominantly white matter tract, and it differs histologically from
the spinal cord both in terms of its cellular environment and or-
ganization. There is also no comparative data on the actual con-
centration of the active metabolites that are achieved locally within
the optic nerve and the spinal cord following intravenous steroid
injections. Several fundamental questions therefore remain
whether extrapolating experimental and clinical data from the
spinal cord to the optic nerve is biologically plausible.
13. Adverse effects
High-dose to megadose steroids are relatively safe, but serious
complications can occur and these need to be considered, especially
if preexisting susceptibility factors are present.43e45 The CRASH
(Corticosteroid Randomisation After Signiﬁcant Head injury) study
was a large randomized controlled trial investigating the effec-
tiveness and safety of steroids in patients with acute traumatic
brain injury.45 Patients presenting within 8 hours of head trauma
were allocated to either placebo or megadose intravenous meth-
ylprednisolone (2 g over 1 hour, followed by 0.4 g/h for 48 hours).
The initial protocol was to recruit 20,000 participants, but the study
was terminated prematurely after 10,008 people had been enrolled
because an interim analysis revealed a detrimental effect in the
steroid arm of the trial. At 6 months of follow-up, the risk of death
was signiﬁcantly higher in the steroid group (25.7%) than in the
placebo group (22.3%), as was the risk of death or severe disability
(38.1% vs. 36.3%, respectively). This landmark trial provides
convincing evidence that steroids should no longer be used in pa-
tients with traumatic brain injury, a conclusion that was also
reached by a recent Cochrane systematic review on this topic.45,46
The recommendations from the CRASH study must therefore be
considered seriously in the subgroup of TON patients who have
sustained signiﬁcant head injuries.21,41
A number of animal models of TON have been developed, and
the most widely used experimental paradigm involves a direct,
mechanical crush injury to the rat's optic nerve.7 In three studies,
rats treated with various regimens of methylprednisolone were
compared with sham controls following an optic nerve crush
injury.47e49 Two studies failed to show any difference in retinal
ganglion cell survival and axonal regeneration between these two
groups.47,48 However, in the third study, steroids exacerbated
P. Yu-Wai-Man / Taiwan Journal of Ophthalmology 5 (2015) 3e8 7retinal ganglion cell loss and there was a signiﬁcant, dose-
dependent decline in axonal counts with increasing doses of ste-
roids.49 Although some caution is needed when extrapolating ev-
idence from animal studies, supraphysiological doses of steroids
could exert a negative effect on neuronal survival by suppressing
key endogenous neuroprotective pathways.50 For this reason, a
maximum daily dose of 1 g intravenous methylprednisolone has
been advocated in TON to minimize the risk of neurotoxicity when
a decision has been made to initiate treatment.51
14. Surgery
Awide range of intra- and extracranial surgical techniques have
been used to achieve optic nerve decompression in TON.52,53
Although the favored intervention is largely dictated by the
expertise available locally and the surgeon's preference, there has
been a shift toward minimally invasive extracranial approaches
employing the transethmoidal, endonasal, or sublabial
routes.16,29,54e57
15. Timing of surgery
The timing of surgery is a relevant issue in the context of trauma
where life-threatening injuries often lead to unavoidable delays
before a formal ophthalmological assessment can be carried out.
Intuitively, the longer the delay, the less likely optic canal decom-
pression would be expected to salvage compromised retinal gan-
glion cells and restore visual function. Based on the limited data
available, there is conﬂicting evidence whether the length of time
between the initial insult and surgical intervention actually impacts
on visual recovery in TON.20,51
16. Optic canal fracture
Some authorities argue that the optic canal should be imaged in
all TON cases, and if a fracture is identiﬁed with a bone fragment
impinging on the optic nerve (Fig. 5), prompt surgical intervention
should be advocated.51,58 The counterargument is that some studies
have actually identiﬁed the presence of an optic canal fracture as a
poor prognostic factor for visual recovery, irrespective of the
treatment modality used.16,22,26,28,29 This makes biological sense,
because a bone fragment is likely to transect a large proportion ofFig. 5. Axial computerized tomography scan showing bone fragments compressing the
right optic nerve in the posterior orbital region. Multiple fractures of the lateral orbital
wall and of the greater wing of the sphenoid can also be noted on the right side.
(Courtesy of Professor Kazuo Shimozato, Aichi-Gakuin University, Nagoya, Japan.)retinal ganglion cell axons resulting in immediate irreversible
injury and decompressing the optic canal in this situation is un-
likely to restore signiﬁcant visual function.
17. Critical analysis
There are no randomized controlled trials on the effectiveness of
surgical optic nerve decompression in TON.20 As part of the IONTS
cohort, three out of 33 patients (10%) who underwent external
surgical decompression suffered postoperative cerebrospinal ﬂuid
leak, with one patient developing meningitis.14 Another case series
reported accidental dural exposure in 5% of patients who under-
went endoscopic optic canal decompression.57 Given the relatively
high rate of spontaneous visual improvement in indirect TON, the
decision to subject a patient to a surgical intervention with
potentially serious complications must be even more circumspect.
18. Practical considerations
There are practical limitations in applying the NASCIS ﬁndings
given the narrow window of opportunity available for initiating
treatment. There are often unavoidable delays in diagnosing TON
when patients have life-threatening injuries that justiﬁably take
precedence before an ophthalmological opinion is sought. If the
patient is unconscious for a prolonged period, visual loss is likely to
be reported late, and even if a clinical diagnosis is made within the
8-hour window, there are obvious ethical considerations to initi-
ating potentially controversial treatment without proper informed
consent. Recent animal studies and the CRASH trial have also
highlighted signiﬁcant gaps in our understanding of central ner-
vous system injuries, and there is an urgent need for further
research into the role of steroids in modulating neuronal recovery
following trauma. The logistics required for an adequately powered
randomized controlled trial in TON are daunting, and practically, it
is unclear whether the resources needed for such a major under-
taking are feasible, both in terms of patient recruitment and stan-
dardization of treatment. There is a relatively high rate of
spontaneous visual recovery in TON, and there is no convincing
evidence that steroids or surgical optic nerve decompression pro-
vides any additional beneﬁt over conservative management alone.
Each case therefore needs to be assessed on an individual basis, and
the patient needs to be made fully aware of both the theoretical
risks suggested by recent studies, and the real risks, albeit rare, of a
serious adverse event with active intervention.
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